Skip to main content
Sanofi India Ltd logo

Sanofi India Ltd — Investor Relations & Filings

Ticker · SANOFI ISIN · INE058A01010 LEI · 335800VFWLEY5V6PYH80 BSE.NS Manufacturing
Open in API
Filings indexed 1,554 across all filing types
Latest filing 2020-02-06 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS SANOFI

About Sanofi India Ltd

https://www.sanofi.in

Sanofi India Ltd focuses on the development, manufacturing, and marketing of a wide range of pharmaceutical products and healthcare solutions. The company operates across several therapeutic areas, including diabetes, cardiology, thrombosis, central nervous system disorders, and consumer healthcare. Its product portfolio includes established brands such as Lantus, Allegra, Combiflam, Amaryl, Avil, and Enterogermina. The organization prioritizes chronic disease management and acute care through a combination of prescription medicines and over-the-counter treatments. By integrating global research capabilities with local manufacturing excellence, the company provides specialized medical solutions aimed at improving patient health outcomes and addressing unmet medical needs.

Recent filings

Filing Released Lang Actions
Updates
Interim / Quarterly Report Classification · 95% confidence The document contains multiple notices of upcoming Board Meetings scheduled in February 2020 to consider and approve unaudited financial results for the quarter and nine months ended December 31, 2019. It includes detailed unaudited financial results tables and notes, indicating substantive financial data and analysis. The presence of quarterly and nine-month financial results with actual figures and management notes confirms this is a comprehensive interim financial report rather than a mere announcement or notice. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2020
2020-02-06 English
Please find enclosed copies of the Notice of the Board Meeting of the Company published today, in newspapers, Business Standard and Sakal.
Interim / Quarterly Report Classification · 95% confidence The document contains multiple notices of upcoming Board Meetings scheduled in February 2020 to consider and approve unaudited financial results for the quarter and nine months ended December 31, 2019. The text includes detailed unaudited financial results tables and notes, indicating substantive financial data and analysis. The presence of financial results for a period shorter than a full fiscal year (quarter and nine months) and the approval by the Board of Directors aligns with the definition of an Interim / Quarterly Report (IR). The document is not merely an announcement of a meeting or a report publication notice but includes actual financial results and explanatory notes. Therefore, the document is best classified as an Interim / Quarterly Report (IR). 9M 2020
2020-02-06 English
Sanofi India Ltd has informed BSE that the meeting of the Board of Directors of the Company will be held on February 25, 2020, inter alia, to:1. Approve the audited accounts for ....
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about an upcoming Board of Directors meeting scheduled for 25th February 2020. The purpose of the meeting includes approving audited accounts for the year ended 31st December 2019 and recommending a final dividend. The document is brief (1143 characters) and serves as an announcement rather than containing the actual audited accounts or dividend details. It does not contain financial data or detailed report content. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement informing about a board meeting and upcoming approvals, not the report itself or a detailed financial document.
2020-02-05 English
Board Meeting — Financial Results/Dividend
Regulatory Filings Classification · 95% confidence The document is a short notice from Sanofi India Limited informing stock exchanges about an upcoming Board of Directors meeting scheduled for 25th February 2020. The agenda includes approval of audited accounts for the year ended 31st December 2019 and recommendation of a final dividend. The document is brief (1143 characters) and serves as an announcement of a meeting rather than the meeting materials or the actual financial report. It does not contain financial data or detailed report content. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement about a board meeting and agenda items, not the actual annual report or dividend notice.
2020-02-05 English
Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/02/2020 ,inter alia, to consider and approve 1. The audited accounts for the ....
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about an upcoming Board of Directors meeting scheduled for 25th February 2020. The purpose of the meeting includes approving audited accounts for the year ended 31st December 2019 and recommending a final dividend. The document is brief (1143 characters) and serves as an announcement rather than containing the actual audited accounts or dividend details. It does not contain financial data or detailed report content. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement informing about a board meeting and upcoming approvals, not the report itself or a detailed financial document.
2020-02-05 English
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its ....
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to stock exchanges regarding the loss of share certificates, referencing Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements). It contains details of shareholders and lost certificates. The document is short (1400 characters) and serves as an official notification to the exchanges rather than a financial report or detailed filing. It does not contain financial data, management changes, voting results, or other report types. This fits the category of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2020-02-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.